Skip to main content
PMC home page
Neuroscience Bulletin logoLink to Neuroscience Bulletin
. 2015 Jan 6;31(1):22–30. doi: 10.1007/s12264-014-1487-3

Atypical features and treatment choices in bipolar disorders: a result of the National Bipolar Mania Pathway Survey in China

Daihui Peng 1, Ting Shen 1, Linda Byrne 2, Chen Zhang 1, Yueqi Huang 1, Xin Yu 3, Jingping Zhao 4, Marita McCabe 2, David Mellor 2, Yiru Fang 1,✉
PMCID: PMC5562638  PMID: 25564191

Abstract

In this study, we examined the point prevalence rate of atypical features in bipolar disorder, and estimated the potential impact of these features on treatment practices in China. Using the atypical features criteria of the Diagnostic and Statistical Manual of the American Psychiatric Association (DSM-IV), we documented the atypical symptoms in 3 906 consecutive participants with bipolar disorder enrolled at 26 psychiatric services across China. We further assessed the association between atypical features and the treatment approaches, including the prescription of antidepressants. The overall point prevalence rate of atypical features was 9.1% among patients with various bipolar disorder subtypes. When the definition was broadened to include atypical features B, the overall rate increased to 11.8%. Interestingly, among patients with the mixed state and remission subtypes, there was a significant difference in the rates of antidepressant medication usage between patients who met and those who did not meet the criteria for atypical features B. These findings indicate a trend of using antidepressants for these two types of patients with atypical features. Further, for both mixed state and remission patients, treatment approaches were related to atypical features B. Our findings provide evidence to assist clinicians to readily recognize atypical features in bipolar subtypes and can propose treatments based on these diagnoses.

Keywords: atypical features, bipolar, treatment, antidepressant

References

  • [1].American Psychiatric Association. Task force on DSM-IV. Diagnostic and statistical manual of mental disorders: DSMIV-TR. 4th ed. 2000. pp. 41–48. [Google Scholar]
  • [2].Angst J, Gamma A, Benazzi F, Ajdacic V, Eich D, Rossler W. Toward a re-definition of subthreshold bipolarity: epidemiology and proposed criteria for bipolar-II, minor bipolar disorders and hypomania. J Affect Disord. 2003;73:133–146. doi: 10.1016/S0165-0327(02)00322-1. [DOI] [PubMed] [Google Scholar]
  • [3].Judd LL, Akiskal HS. The prevalence and disability of bipolar spectrum disorders in the US population: re-analysis of the ECA database taking into account subthreshold cases. J Affect Disord. 2003;73:123–131. doi: 10.1016/S0165-0327(02)00332-4. [DOI] [PubMed] [Google Scholar]
  • [4].Merikangas KR, Akiskal HS, Angst J, Greenberg PE, Hirschfeld RM, Petukhova M, et al. Lifetime and 12-month prevalence of bipolar spectrum disorder in the National Comorbidity Survey replication. Arch Gen Psychiatry. 2007;64:543–552. doi: 10.1001/archpsyc.64.5.543. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [5].Merikangas KR, Jin R, He JP, Kessler RC, Lee S, Sampson NA, et al. Prevalence and correlates of bipolar spectrum disorder in the world mental health survey initiative. Arch Gen Psychiatry. 2011;68:241–251. doi: 10.1001/archgenpsychiatry.2011.12. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [6].Regier DA, Farmer ME, Rae DS, Locke BZ, Keith SJ, Judd LL, et al. Comorbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemiologic Catchment Area (ECA) study. JAMA. 1990;264:2511–2518. doi: 10.1001/jama.1990.03450190043026. [DOI] [PubMed] [Google Scholar]
  • [7].Phillips MR, Zhang J, Shi Q, Song Z, Ding Z, Pang S, et al. Prevalence, treatment, and associated disability of mental disorders in four provinces in China during 2001-05: an epidemiological survey. Lancet. 2009;373:2041–2053. doi: 10.1016/S0140-6736(09)60660-7. [DOI] [PubMed] [Google Scholar]
  • [8].Asnis GM, McGinn LK, Sanderson WC. Atypical depression: clinical aspects and noradrenergic function. Am J Psychiatry. 1995;152:31–36. doi: 10.1176/ajp.152.1.31. [DOI] [PubMed] [Google Scholar]
  • [9].Kendler KS, Eaves LJ, Walters EE, Neale MC, Heath AC, Kessler RC. The identification and validation of distinct depressive syndromes in a population-based sample of female twins. Arch Gen Psychiatry. 1996;53:391–399. doi: 10.1001/archpsyc.1996.01830050025004. [DOI] [PubMed] [Google Scholar]
  • [10].Rabkin JG, Stewart JW, Quitkin FM, McGrath PJ, Harrison WM, Klein DF. Should atypical depression be included in DSM-IV. DSM-IV Sourcebook. 1996;2:239–260. [Google Scholar]
  • [11].Benazzi F. Atypical depression in private practice depressed outpatients: a 203-case study. Compr Psychiatry. 1999;40:80–83. doi: 10.1016/S0010-440X(99)90081-0. [DOI] [PubMed] [Google Scholar]
  • [12].Benazzi F. Should mood reactivity be included in the DSM-IV atypical features specifier? Eur Arch Psychiatry Clin Neurosci. 2002;252:135–140. doi: 10.1007/s00406-002-0373-6. [DOI] [PubMed] [Google Scholar]
  • [13].Perugi G, Akiskal HS, Lattanzi L, Cecconi D, Mastrocinque C, Patronelli A, et al. The high prevalence of “soft” bipolar (II) features in atypical depression. Compr Psychiatry. 1998;39:63–71. doi: 10.1016/S0010-440X(98)90080-3. [DOI] [PubMed] [Google Scholar]
  • [14].Posternak MA, Zimmerman M. The prevalence of atypical features across mood, anxiety, and personality disorders. Compr Psychiatry. 2002;43:253–262. doi: 10.1053/comp.2002.33498. [DOI] [PubMed] [Google Scholar]
  • [15].Thase ME. Recognition and diagnosis of atypical depression. J Clin Psychiatry. 2007;68Suppl8:11–16. [PubMed] [Google Scholar]
  • [16].Akiskal HS, Walker P, Puzantian VR, King D, Rosenthal TL, Dranon M. Bipolar outcome in the course of depressive illness: phenomenologic, familial, and pharmacologic predictors. J Affect Disord. 1983;5:115–128. doi: 10.1016/0165-0327(83)90004-6. [DOI] [PubMed] [Google Scholar]
  • [17].Robertson HA, Lam RW, Stewart JN, Yatham LN, Tam EM, Zis AP. Atypical depressive symptoms and clusters in unipolar and bipolar depression. Acta Psychiatr Scand. 1996;94:421–427. doi: 10.1111/j.1600-0447.1996.tb09884.x. [DOI] [PubMed] [Google Scholar]
  • [18].Quitkin FM, Stewart JW, McGrath PJ, Liebowitz MR. Phenelzine versus imipramine in the treatment of probable atypical depression: defining syndrome boundaries of selective MAOI responders. Am J Psychiatry. 1988;145:306–311. doi: 10.1176/ajp.145.10.1322-b. [DOI] [PubMed] [Google Scholar]
  • [19].Sotsky SM, Simmens SJ. Pharmacotherapy response and diagnostic validity in atypical depression. J Affect Disord. 1999;54:237–247. doi: 10.1016/S0165-0327(99)00014-2. [DOI] [PubMed] [Google Scholar]
  • [20].Stewart J, Thase M. Treating DSM-IV depression with atypical features. J Clin Psychiatry. 2007;68:e10–e10. doi: 10.4088/JCP.0407e10. [DOI] [PubMed] [Google Scholar]
  • [21].Gijsman HJ, Geddes JR, Rendell JM, Nolen WA, Goodwin GM. Antidepressants for bipolar depression: a systematic review of randomized, controlled trials. Am J Psychiatry. 2004;161:1537–1547. doi: 10.1176/appi.ajp.161.9.1537. [DOI] [PubMed] [Google Scholar]
  • [22].Sachs GS, Nierenberg AA, Calabrese JR, Marangell LB, Wisniewski SR, Gyulai L, et al. Effectiveness of adjunctive antidepressant treatment for bipolar depression. N Engl J Med. 2007;356:1711–1722. doi: 10.1056/NEJMoa064135. [DOI] [PubMed] [Google Scholar]
  • [23].American Psychiatric Association. Pra ctice guideline for the treatment of patients with bipolar disorder (revision) Am J Psychiatry. 2002;159:4. [PubMed] [Google Scholar]
  • [24].Grunze H, Vieta E, Goodwin GM, Bowden C, Licht RW, Möller HJ, et al. The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders: Update 2012 on the long-term treatment of bipolar disorder. World J Biol Psychiatry. 2013;14:154–219. doi: 10.3109/15622975.2013.770551. [DOI] [PubMed] [Google Scholar]
  • [25].National Collabor ating Centre for Mental Health. Bipolar Disorder: The Management of Bipolar Disorder in Adults, Children, and Adolescents. Primary and Secondary Care. Leicester, UK: British Psychological Society; 2006. [PubMed] [Google Scholar]
  • [26].Shen Q, Liu T, Zhan H, Ma X, Wang G, Tian C. Practice guideline for prevention and treatment of bipolar disorder (in Chinese) Beijing (China): Chinese Medical Association; 2007. [Google Scholar]
  • [27].Si T, Shu L, Yu X, Ma C, Wang G, Bai P, et al. A crosssectional study on treatment patterns of bipolar disorders in China in 2006. Chin J Psychiatry. 2012;45:29–34. [Google Scholar]
  • [28].Angst J, Gamma A, Bowden C, Azorin J, Perugi G, Vieta E, et al. Diagnostic criteria for bipolarity based on an international sample of 5,635 patients with DSM-IV major depressive episodes. Eur Arch Psychiatry Clin Neurosci. 2012;262:3–11. doi: 10.1007/s00406-011-0228-0. [DOI] [PubMed] [Google Scholar]
  • [29].Benazzi F. Prevalen ce of bipolar II disorder in outpatient depression: a 203-case study in private practice. J Affect Disord. 1997;43:163–166. doi: 10.1016/S0165-0327(96)01421-8. [DOI] [PubMed] [Google Scholar]
  • [30].Benazzi F. Sensitivi ty and specificity of clinical markers for the diagnosis of bipolar II disorder. Compr Psychiatry. 2001;42:461–465. doi: 10.1053/comp.2001.27901. [DOI] [PubMed] [Google Scholar]
  • [31].Benazzi F. Bipolar di sorder-focus on bipolar II disorder and mixed depression. Lancet. 2007;369:935–945. doi: 10.1016/S0140-6736(07)60453-X. [DOI] [PubMed] [Google Scholar]
  • [32].Chen FZ, Xiang YT, Lu Z, Wang G, Hu C, Kilbourne AM, et al. Characteristics of unrecognised bipolar disorder in patients treated for major depressive disorder in china: general versus psychiatric hospitals. East Asian Arch Psychiatry. 2013;23:139–143. [PubMed] [Google Scholar]
  • [33].Carta MG, Aguglia E, Balestrieri M, Calabrese JR, Caraci F, Dell'Osso L, et al. The lifetime prevalence of bipolar disorders and the use of antidepressant drugs in bipolar depression in Italy. J Affect Disord. 2012;136:775–780. doi: 10.1016/j.jad.2011.09.041. [DOI] [PubMed] [Google Scholar]
  • [34].Goldberg JF, Brooks JO, 3rd, Kurita K, Hoblyn JC, Ghaemi SN, Perlis RH, et al. Depressive illness burden associated with complex polypharmacy in patients with bipolar disorder: findings from the STEP-BD. J Clin Psychiatry. 2009;70:155–162. doi: 10.4088/JCP.08m04301. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [35].Greil W, Haberle A, Haueis P, Grohmann R, Russmann S. Pharmacotherapeutic trends in 2231 psychiatric inpatients with bipolar depression from the International AMSP Project between 1994 and 2009. J Affect Disord. 2012;136:534–542. doi: 10.1016/j.jad.2011.10.033. [DOI] [PubMed] [Google Scholar]
  • [36].Albert Y. The use of antide pressants for treating bipolar depression: a clinical controversy. Shanghai Arch Psychiatry. 2011;23:175–177. [Google Scholar]
  • [37].Geddes JR, Miklowitz DJ. Tre atment of bipolar disorder. Lancet. 2013;381:1672–1682. doi: 10.1016/S0140-6736(13)60857-0. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Neuroscience Bulletin are provided here courtesy of Springer

RESOURCES